Jonathan Strober, MD, discusses promising results from the VIBRANCE-MG trial, highlighting nipocalimab's safety and efficacy for pediatric myasthenia gravis.
Immune-check point inhibitors used in chemotherapy have an increased risk of noninfectious uveitis (inflammation of the eye wall) and myasthenia gravis (MG). People who use immune-check point ...
Generalized myasthenia gravis is Uplizna’s second new indication this year, after the FDA cleared the anti-CD19 antibody for IgG4-related disease in April.
Discover the latest breakthroughs in myasthenia gravis treatment, including rozanolixizumab and nipocalimab, and insights on ...
DUBLIN--(BUSINESS WIRE)--The "Ophthalmology Pipeline Database - 2018" report has been added to ResearchAndMarkets.com's offering. Ophthalmology Pipeline Highlights Database - 2018, provides most up-to ...
Myasthenia gravis, or MG, is "a chronic autoimmune neuromuscular disorder that causes muscle weakness and fatigue," says Hesterlee. It occurs "when a person’s immune system is essentially attacking ...
Myasthenia gravis is an autoimmune disease that affects the transmission of signals from nerves to muscles. The name myasthenia gravis comes from Greek and Latin words meaning "grave muscle weakness." ...
With treatment, myasthenia gravis can generally be controlled. In fact, about 50 percent of people who have their thymus gland removed may experience long-lasting, complete remission of myasthenia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback